cropped color_logo_with_background.png

Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma

Study Purpose

Despite surgery and first-line standard of care which consist of radiotherapy with concomitant and adjuvant temozolomide, all patients with glioblastoma (GB) will experience relapse. At the time of recurrence, therapeutic options include surgery or reirradiation in selected cases, while in other cases, bevacizumab, approved by Food and Drug Administration (FDA) but not European Medicines Agency (EMA), is the preferred option worldwide. Primary and acquired resistance to bevacizumab has been explored without definitive finding. Biomarkers able to predict response to antiangiogenic agents and particularly to bevacizumab are an unmet medical need. We have showed that a low Matrix metallopeptidase 9 (MMP9) or a high Matrix metallopeptidase 2 (MMP2) baseline plasma levels were associated with a high response rate and a prolonged Progression-free survival (PFS) and overall survival (OS) in recurrent GB patients treated with bevacizumab but not with cytotoxic chemotherapy. We also observed that MMP9 plasma level decreased during bevacizumab treatment and tend to increase at progression. Finally, in a retrospective analysis performed in the Avaglio trial (a randomized phase III trial that tested bevacizumab versus placebo in addition to standard of care in patients with newly diagnosed glioblastoma), a low plasma level of MMP9 at baseline predicted consistently PFS and OS gain associated to bevacizumab. These results are consistent with the role of MMP9 in vasculogenesis, since MMP9 contribute to the recruitment of circulating endothelial and myeloid precursors, an alternative vascularization process which is in part independent of the vascular endothelial growth factor (VEGF) pathway. Monoclonal Antibody (GS) 5745 is specifically directed against MMP9. First in human phase I study has been completed. Development is ongoing. Our results strongly support a role for MMP9 in the primary or acquired resistance to bevacizumab. Therefore, we hypothesize that the Monoclonal Antibody GS5745 may overcome resistance to bevacizumab through a specific inhibition of MMP9. While a preclinical program is initiated in our lab, the proposed phase I study is the first step to analyze the tolerance, determine the recommended dose of the combination and explore the impact of GS5745 on MMP9 plasma levels and multimodal imaging in patients with recurrent glioblastoma. Objective: Determine the safety profile and tolerability of GS5745 given in combination with a fixed dose of bevacizumab in patients with recurrent GB in terms of Dose-Limiting Toxicities. Multicenter, open label, dose-finding study of GS5745 in combination with bevacizumab administered at a fixed dose; both drugs will be administered once every two weeks for a total treatment duration of a maximum of 12 months. Before initiation of each new dose level, a meeting between the sponsor, the coordinator, the investigators and an independent external expert will take place to decide jointly the next dose.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Histologically confirmed diagnosis of isocitrate dehydrogenase (IDH) wild-type glioblastoma.
  • - First or second recurrence after standard treatment with combined chemo-irradiation.
  • - Patients must have measurable tumour disease as defined by Response assessment in neuro-oncology (RANO) criteria within 2 weeks before the first drug administration.
  • - Stable or decreasing dose of corticosteroids within 5 days prior first administration.
  • - Karnofsky Performance Status superior at 60% - Negative serum or urine pregnancy test done inferior or egal at 7 days prior to registration, for women of childbearing potential only.
  • - Provide informed written consent.

Exclusion Criteria:

  • - Major surgery (including craniotomy) within 4 weeks prior to the first day of study drug administration.
  • - Chemotherapy within 4 weeks prior to the first day of study drug administration.
  • - Radiotherapy within 3 months prior the diagnosis of progression.
  • - Prior treatment with bevacizumab or other vascular endothelial growth factor (VEGF) receptor targeted agent.
  • - Evidence of Central Nervous System (CNS) haemorrhage on the baseline MRI.
  • - Other conditions reported to exclude bevacizumab administration.
  • - Men or women of childbearing potential who are unwilling to employ adequate contraception during this study.
  • - Concomitant serious immunocompromised status.
  • - Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements.
  • - Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm.
  • - Other active malignancy within 5 years of registration.
Exceptions: Non-melanotic skin cancer or carcinoma-in-situ of the cervix

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03631836
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Assistance Publique Hopitaux De Marseille
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Jean-Olivier ARNAUD, Director
Principal Investigator Affiliation Assistance Publique des Hôpitaux de Marseille
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Unknown status
Countries France
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Glioblastoma
Arms & Interventions

Arms

Experimental: Combinaton monoclonal therapeutic antibody and bevacizumab

Determine the safety profile and tolerability of monoclonal therapeutic antibody given in combination with a fixed dose of bevacizumab in patients with recurrent glioblastoma in terms of Dose-Limiting Toxicities

Interventions

Drug: - Monoclonal antibody

3 doses of Monoclonal antibody could be tested

Drug: - Bevacizumab

fixed dose of bevacizumab (10 mg/ kg every two weeks)

Biological: - Blood sample

Evaluate the biomarkers plasma levels during administration of drug

Device: - Dynamic Contrast Enhanced magnetic resonance imaging (DCE-MRI)

Assess antiangiogenic effects by DCE-MRI

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Marseille, France

Status

Address

Assistance Publique des Hôpitaux de Marseille

Marseille, , 13354

Site Contact

Olivier CHINOT, PU-PH

[email protected]

491385500 #+33